Roche in an agreement with ONVO, could possibly help CRIS
Genentech is also working with Curis(CRIS), in the development of breast cancer and other tumor drug discovery. If they could use the 3D liver assays to test the toxicity of these drugs it would move them along faster. Some of the drugs CRIS is developing are in phase 1 trials. Imagine if this is what they are doing with these 3D assays how much faster it could move these drugs along and create royalties when drugs are developed. Both companies know getting these drugs to market brings in the money. I follow many companies to try and see possible interactions between each other. This is just my opinion of what is going on.